Uber Health hires board-certified physician as its first chief medical officer

Uber’s healthcare division, Uber Health, has hired its first chief medical officer, the company announced Tuesday.

Michael Cantor, MD, will lead the San Francisco-based health firm in its efforts to close existing care gaps and reduce costs for patients, providers and payers. As a board-certified geriatrician with 20-plus years of medical experience, Cantor has unique insight into designing clinical programs for older adults and vulnerable populations.

“I’ve seen first-hand how important leveraging transportation is in both improving clinical outcomes and creating care systems that allow patients to live independently in their community,” Cantor said in a statement. “That’s why I’m excited to join Uber as the team continues to build relevant solutions that aren’t just more efficient for healthcare providers but also help bring care more directly to patients at home on a community-wide scale.”

Uber Health says demand for its services has never been higher, recording a 71% increase in gross bookings from the fourth quarter of 2020 to Q4 of 2021.

The technology company first launched its health platform in 2018, offering non-emergency transport and partnering with healthcare organizations to reduce missed appointments. It’s collaborated with more than 3,000 health customers, including EMR giant Cerner, care coordination specialist Carisk, pharma company Scriptdrop and others.

""

Matt joined Chicago’s TriMed team in 2018 covering all areas of health imaging after two years reporting on the hospital field. He holds a bachelor’s in English from UIC, and enjoys a good cup of coffee and an interesting documentary.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.